Moreover, clinical studies reported that plasmatic concentrations of GFAP, NfL and pTau 181 were correlated with the concentrations of the same biomarkers in the CSF, being increased in AD patients compared to Healthy Controls (HC) (16). The gene discussed is GFAP; the disease is Alzheimer disease.